Biofidelity

Biofidelity is a pioneering startup operating in the genomics sector, aiming to revolutionize human health and the world we live in. The company develops innovative technologies that unlock the potential of genomics, which is the study of all of a person's genes (the genome), including interactions of those genes with each other and with the person's environment. Biofidelity's primary offering is ASPYRE-Lung, a product designed to expedite the process of obtaining vital biomarker data for lung cancer patients. Biomarkers are biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.

ASPYRE-Lung identifies all guideline recommended biomarkers that correlate with more than 25 life-saving targeted therapies for patients with lung cancer, in a fraction of the time and at a fraction of the cost of traditional sequencing technologies. This means that patients can receive personalized treatment plans faster and more affordably.

Biofidelity's business model is centered around its patented molecular chemistry technology, ASPYRE, which simplifies and accelerates the detection of actionable genomic biomarkers. This technology can be used with existing PCR (Polymerase Chain Reaction) instruments, which are common laboratory equipment used to make copies of a specific DNA segment. This makes precision genomic testing more accessible to a larger number of patients worldwide.

In essence, Biofidelity is making genomic analysis less complex, faster, and more accurate, thereby making it more accessible to people around the world. The company is committed to overcoming the barriers that have prevented many patients from experiencing the benefits of targeted therapies.

Keywords: Genomics, Biomarkers, Lung Cancer, Targeted Therapies, ASPYRE-Lung, Precision Medicine, Molecular Chemistry, PCR Instruments, Genomic Analysis, Accessible Healthcare.